Effects of Intranasal Oxytocin Administration on Social Influence Effects on Pain
NCT ID: NCT03060031
Last Updated: 2019-06-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
51 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-06-21
Study Completion Date
2019-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This experiment will explore the joint effects of social information, social support, associative learning, and oxytocin on the development of placebo analgesia. The investigators predict that socially transmitted placebo effects will be enhanced by nasal administration of oxytocin, whereas associative learning effects on pain will not be altered by this pharmacological manipulation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxytocin Effects on Self and Other Processing
NCT02963194
Social Behavior
COMPLETED
NA
Oxytocin Effects on the Tolerance of Infidelity
NCT02733237
Healthy
COMPLETED
NA
Oxytocin and Social Cognition
NCT01606462
Healthy Male Volunteers
COMPLETED
PHASE1
Influence of Oxytocin on Approach-avoidance Tendencies to Social and Non-social Stimuli
NCT04443647
Basic Science
COMPLETED
NA
The Influence of Intranasal Oxytocin on Communication
NCT02415920
Healthy
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
The placebo literature suggests that both conceptual (i.e. socially instructed beliefs) and associative learning processes are critical for the genesis of placebo effects. Several studies have performed placebo 'conditioning' (associating a sham treatment with reduced pain through repeated experience) but interfered with conceptual processing by informing subjects that the intensity of the stimulus was being lowered. This manipulation prevented the attribution of pain reductions to the placebo treatment during the learning process. These studies showed no conditioned analgesia. However, when the same 'conditioning' was performed without the verbal explanation for why the treatment seemed to work, robust placebo effects were created. Conceptual processes appear to be critical. Conversely, several studies have manipulated conceptual expectations alone, by manipulating verbal instructions, and have found markedly reduced or absent placebo analgesia on both pain report and brain event-related potentials. Learning by experience also seems to be critical.
These studies separately have led to the conclusions that 'expectancy' and 'conditioning' are each critical processes, and debates have focused on which one is the driver of placebo effects. The investigators propose another view: Both processes are critical, and they interact. Experience drives changes in value learning systems, but in any type of value learning, there is a 'credit assignment' problem, and the brain must decide which cue-outcome associations to update as a result of experience: Is the pain reduced because the treatment was effective or because the cause of pain changed? Conceptual processes fill the gap, drawing on explicit memory and generalization from similar past experiences to solve the credit assignment problem, creating analgesia if experienced relief is attributed to the treatment. This view is compatible with older information based theories of conditioning and new evidence that rats and humans alike maintain expectancies about specific outcomes and mental models of contingencies that are distinct from associative learning. In spite of dozens of published studies demonstrating effective placebo analgesia with the established paradigm the investigators use, the precise nature of the learning that occurs is unknown, because placebo analgesia has not typically been studied from a learning-systems perspective. The aim of the present study is to assess the influence of social information and associative learning on placebo analgesia.
In addition, interactions between neurochemical systems and placebo analgesia have hardly been explored, and this proposal represents a significant effort in that regard. For example, oxytocin interacts synergistically with opioids in the PAG (periaqueductal gray) (and CCK (Cholecystokinin)) to relieve pain, and in a separate literature reliably increases trust and reduces anxiety in interpersonal situations. In spite of the fact that oxytocin has been proposed as central to the placebo effect and can be administered to humans with no known subjective effects or side effects, its role in placebo analgesia has not been explored extensively. The experiment proposed here will clarify the roles of the oxytocin system and its contributions to social facilitation of analgesia, and will be instrumental in developing a systems-based model of placebo effects.
Experimental Design:
Participants will perform two tasks in each experimental session. First, they will perform a social-influence and learning task to investigate the effects of oxytocin on social instruction effects and learning on pain. Second, they will perform a social-support during pain, to test the effects of oxytocin on the pain-alleviating effects of social support during pain.
The placebo literature suggests that both conceptual (i.e. socially instructed beliefs) and associative learning processes are critical for the genesis of placebo effects. Several studies have performed placebo 'conditioning' (associating a sham treatment with reduced pain through repeated experience) but interfered with conceptual processing by informing subjects that the intensity of the stimulus was being lowered. This manipulation prevented the attribution of pain reductions to the placebo treatment during the learning process. These studies showed no conditioned analgesia. However, when the same 'conditioning' was performed without the verbal explanation for why the treatment seemed to work, robust placebo effects were created. Conceptual processes appear to be critical. Conversely, several studies have manipulated conceptual expectations alone, by manipulating verbal instructions, and have found markedly reduced or absent placebo analgesia on both pain report and brain event-related potentials. Learning by experience also seems to be critical.
These studies separately have led to the conclusions that 'expectancy' and 'conditioning' are each critical processes, and debates have focused on which one is the driver of placebo effects. The investigators propose another view: Both processes are critical, and they interact. Experience drives changes in value learning systems, but in any type of value learning, there is a 'credit assignment' problem, and the brain must decide which cue-outcome associations to update as a result of experience: Is the pain reduced because the treatment was effective or because the cause of pain changed? Conceptual processes fill the gap, drawing on explicit memory and generalization from similar past experiences to solve the credit assignment problem, creating analgesia if experienced relief is attributed to the treatment. This view is compatible with older information based theories of conditioning and new evidence that rats and humans alike maintain expectancies about specific outcomes and mental models of contingencies that are distinct from associative learning. In spite of dozens of published studies demonstrating effective placebo analgesia with the established paradigm the investigators use, the precise nature of the learning that occurs is unknown, because placebo analgesia has not typically been studied from a learning-systems perspective. The aim of the present study is to assess the influence of social information and associative learning on placebo analgesia.
In addition, interactions between neurochemical systems and placebo analgesia have hardly been explored, and this proposal represents a significant effort in that regard. For example, oxytocin interacts synergistically with opioids in the PAG (periaqueductal gray) (and CCK (Cholecystokinin)) to relieve pain, and in a separate literature reliably increases trust and reduces anxiety in interpersonal situations. In spite of the fact that oxytocin has been proposed as central to the placebo effect and can be administered to humans with no known subjective effects or side effects, its role in placebo analgesia has not been explored extensively. The experiment proposed here will clarify the roles of the oxytocin system and its contributions to social facilitation of analgesia, and will be instrumental in developing a systems-based model of placebo effects.
Experimental Design:
Participants will perform two tasks in each experimental session. First, they will perform a social-influence and learning task to investigate the effects of oxytocin on social instruction effects and learning on pain. Second, they will perform a social-support during pain, to test the effects of oxytocin on the pain-alleviating effects of social support during pain.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pain
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxytocin
Each participant will undergo pain tasks after self-administration of oxytocin
Group Type
EXPERIMENTAL
Oxytocin
Intervention Type
DRUG
Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
Placebo
Each participant will undergo pain tasks after self-administration of placebo
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
Intervention Type
DRUG
Placebo
Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Syntocinon
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is a volunteer between 18 and 40 years of age.
* If female, subject is non-lactating, not pregnant, and using a reliable contraception method
* Subject is able to read and speak English.
* Subject is able and willing to provide written informed consent.
* Subject is able to understand and follow the instructions of the investigator and understand all screening questionnaires.
* Subject is in good health.
* For participants to be eligible for all tasks of the study, the participant must have a romantic partner and be willing to bring the partner to the study session.
* If female, subject is non-lactating, not pregnant, and using a reliable contraception method
* Subject is able to read and speak English.
* Subject is able and willing to provide written informed consent.
* Subject is able to understand and follow the instructions of the investigator and understand all screening questionnaires.
* Subject is in good health.
* For participants to be eligible for all tasks of the study, the participant must have a romantic partner and be willing to bring the partner to the study session.
Exclusion Criteria
* Tests positive on the 14 panel poly-substance urine drug screen for illicit substances (e.g., marijuana (THC), cocaine (COC), phencyclidine (PCP), amphetamine (AMP), ecstasy (MDMA), methamphetamine (Mamp), opiates (OPI), oxycodone (OXY), methadone (MTD), barbiturates (BAR), benzodiazepines (BZO), buprenorphine (BUP), tricyclic antidepressants (TCA), propoxyphene (PPX))
* Chronic Pain
* Do not have the ability to tolerate heat pain applied to the forearm
* Have temporary abnormal levels of pain
* Have score of \> 19 using the Center for Disease and Epidemiology Depression Scale
* Current treatment (e.g., medications or therapy) for psychiatric disorders, including mood, anxiety, substance abuse, Attention-deficit/hyperactivity disorder (ADHD), psychosis; Neurological disorders (e.g., taking dopamine agonists for Parkinson's); Cardiovascular disease or medication (e.g., taking ACE (angiotensin-converting-enzyme) inhibitors for cardiac remodeling)
* Frequent smoking (\> 5 cigarettes / day); frequent alcohol use (\>14 drinks / week); frequent migraines (\> 5 / month on average) or a history of neurologic disease or neuropathic pain.
* Any allergy to Oxytocin
* Chronic Pain
* Do not have the ability to tolerate heat pain applied to the forearm
* Have temporary abnormal levels of pain
* Have score of \> 19 using the Center for Disease and Epidemiology Depression Scale
* Current treatment (e.g., medications or therapy) for psychiatric disorders, including mood, anxiety, substance abuse, Attention-deficit/hyperactivity disorder (ADHD), psychosis; Neurological disorders (e.g., taking dopamine agonists for Parkinson's); Cardiovascular disease or medication (e.g., taking ACE (angiotensin-converting-enzyme) inhibitors for cardiac remodeling)
* Frequent smoking (\> 5 cigarettes / day); frequent alcohol use (\>14 drinks / week); frequent migraines (\> 5 / month on average) or a history of neurologic disease or neuropathic pain.
* Any allergy to Oxytocin
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Boulder
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tor Wager
Director, Cognitive and Affective Neuroscience Laboratory; Professor, Department of Psychology and Neuroscience and the Institute for Cognitive Science
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tor D Wager, Ph. D.
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Boulder
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Translational Research Center
Boulder, Colorado, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Montgomery GH, Kirsch I. Classical conditioning and the placebo effect. Pain. 1997 Aug;72(1-2):107-13. doi: 10.1016/s0304-3959(97)00016-x.
Reference Type
BACKGROUND
Morton DL, Watson A, El-Deredy W, Jones AK. Reproducibility of placebo analgesia: Effect of dispositional optimism. Pain. 2009 Nov;146(1-2):194-8. doi: 10.1016/j.pain.2009.07.026. Epub 2009 Aug 18.
Reference Type
BACKGROUND
Watson A, El-Deredy W, Iannetti GD, Lloyd D, Tracey I, Vogt BA, Nadeau V, Jones AK. Placebo conditioning and placebo analgesia modulate a common brain network during pain anticipation and perception. Pain. 2009 Sep;145(1-2):24-30. doi: 10.1016/j.pain.2009.04.003. Epub 2009 Jun 11.
Reference Type
BACKGROUND
Watson A, El-Deredy W, Vogt BA, Jones AK. Placebo analgesia is not due to compliance or habituation: EEG and behavioural evidence. Neuroreport. 2007 May 28;18(8):771-5. doi: 10.1097/WNR.0b013e3280c1e2a8.
Reference Type
BACKGROUND
Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia-- imaging a shared neuronal network. Science. 2002 Mar 1;295(5560):1737-40. doi: 10.1126/science.1067176. Epub 2002 Feb 7.
Reference Type
BACKGROUND
Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM, Cohen JD. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004 Feb 20;303(5661):1162-7. doi: 10.1126/science.1093065.
Reference Type
BACKGROUND
Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Nichols TE, Stohler CS. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci. 2005 Aug 24;25(34):7754-62. doi: 10.1523/JNEUROSCI.0439-05.2005.
Reference Type
BACKGROUND
Colloca L, Tinazzi M, Recchia S, Le Pera D, Fiaschi A, Benedetti F, Valeriani M. Learning potentiates neurophysiological and behavioral placebo analgesic responses. Pain. 2008 Oct 15;139(2):306-314. doi: 10.1016/j.pain.2008.04.021. Epub 2008 Jun 6.
Reference Type
BACKGROUND
Kirsch I. Conditioning, expectancy, and the placebo effect: comment on Stewart-Williams and Podd (2004). Psychol Bull. 2004 Mar;130(2):341-3; discussion 344-5. doi: 10.1037/0033-2909.130.2.341.
Reference Type
BACKGROUND
Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull. 2004 Mar;130(2):324-40. doi: 10.1037/0033-2909.130.2.324.
Reference Type
BACKGROUND
Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain. 1990 Oct;43(1):121-128. doi: 10.1016/0304-3959(90)90057-K.
Reference Type
BACKGROUND
Rescorla RA. Pavlovian conditioning. It's not what you think it is. Am Psychol. 1988 Mar;43(3):151-60. doi: 10.1037//0003-066x.43.3.151. No abstract available.
Reference Type
BACKGROUND
Schoenbaum G, Roesch M. Orbitofrontal cortex, associative learning, and expectancies. Neuron. 2005 Sep 1;47(5):633-6. doi: 10.1016/j.neuron.2005.07.018.
Reference Type
BACKGROUND
Balleine BW, O'Doherty JP. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology. 2010 Jan;35(1):48-69. doi: 10.1038/npp.2009.131.
Reference Type
BACKGROUND
Ostlund SB, Balleine BW. Lesions of medial prefrontal cortex disrupt the acquisition but not the expression of goal-directed learning. J Neurosci. 2005 Aug 24;25(34):7763-70. doi: 10.1523/JNEUROSCI.1921-05.2005.
Reference Type
BACKGROUND
Balleine BW, Dickinson A. Goal-directed instrumental action: contingency and incentive learning and their cortical substrates. Neuropharmacology. 1998 Apr-May;37(4-5):407-19. doi: 10.1016/s0028-3908(98)00033-1.
Reference Type
BACKGROUND
Schoenbaum G, Roesch MR, Stalnaker TA, Takahashi YK. A new perspective on the role of the orbitofrontal cortex in adaptive behaviour. Nat Rev Neurosci. 2009 Dec;10(12):885-92. doi: 10.1038/nrn2753. Epub 2009 Nov 11.
Reference Type
BACKGROUND
Yang J, Liang JY, Li P, Pan YJ, Qiu PY, Zhang J, Hao F, Wang DX. Oxytocin in the periaqueductal gray participates in pain modulation in the rat by influencing endogenous opiate peptides. Peptides. 2011 Jun;32(6):1255-61. doi: 10.1016/j.peptides.2011.03.007. Epub 2011 Mar 23.
Reference Type
BACKGROUND
Ge Y, Lundeberg T, Yu LC. Blockade effect of mu and kappa opioid antagonists on the anti-nociception induced by intra-periaqueductal grey injection of oxytocin in rats. Brain Res. 2002 Feb 15;927(2):204-7. doi: 10.1016/s0006-8993(01)03346-7.
Reference Type
BACKGROUND
Yang J, Li P, Liang JY, Pan YJ, Yan XQ, Yan FL, Hao F, Zhang XY, Zhang J, Qiu PY, Wang DX. Oxytocin in the periaqueductal grey regulates nociception in the rat. Regul Pept. 2011 Aug 8;169(1-3):39-42. doi: 10.1016/j.regpep.2011.04.007. Epub 2011 May 3.
Reference Type
BACKGROUND
Reeta Kh, Mediratta PK, Rathi N, Jain H, Chugh C, Sharma KK. Role of kappa- and delta-opioid receptors in the antinociceptive effect of oxytocin in formalin-induced pain response in mice. Regul Pept. 2006 Jul 15;135(1-2):85-90. doi: 10.1016/j.regpep.2006.04.004. Epub 2006 May 19.
Reference Type
BACKGROUND
Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005 Jun 2;435(7042):673-6. doi: 10.1038/nature03701.
Reference Type
BACKGROUND
Theodoridou A, Rowe AC, Penton-Voak IS, Rogers PJ. Oxytocin and social perception: oxytocin increases perceived facial trustworthiness and attractiveness. Horm Behav. 2009 Jun;56(1):128-32. doi: 10.1016/j.yhbeh.2009.03.019. Epub 2009 Apr 1.
Reference Type
BACKGROUND
Zak PJ, Kurzban R, Matzner WT. Oxytocin is associated with human trustworthiness. Horm Behav. 2005 Dec;48(5):522-7. doi: 10.1016/j.yhbeh.2005.07.009. Epub 2005 Aug 18.
Reference Type
BACKGROUND
Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009 Jul;34(6):917-23. doi: 10.1016/j.psyneuen.2009.01.005. Epub 2009 Feb 25.
Reference Type
BACKGROUND
Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry. 2003 Dec 15;54(12):1389-98. doi: 10.1016/s0006-3223(03)00465-7.
Reference Type
BACKGROUND
Bryant RA, Hung L, Guastella AJ, Mitchell PB. Oxytocin as a moderator of hypnotizability. Psychoneuroendocrinology. 2012 Jan;37(1):162-6. doi: 10.1016/j.psyneuen.2011.05.010. Epub 2011 Jun 8.
Reference Type
BACKGROUND
Alvares GA, Hickie IB, Guastella AJ. Acute effects of intranasal oxytocin on subjective and behavioral responses to social rejection. Exp Clin Psychopharmacol. 2010 Aug;18(4):316-21. doi: 10.1037/a0019719.
Reference Type
BACKGROUND
Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010 Apr 1;67(7):692-4. doi: 10.1016/j.biopsych.2009.09.020. Epub 2009 Nov 7.
Reference Type
BACKGROUND
Unkelbach C, Guastella AJ, Forgas JP. Oxytocin selectively facilitates recognition of positive sex and relationship words. Psychol Sci. 2008 Nov;19(11):1092-4. doi: 10.1111/j.1467-9280.2008.02206.x. No abstract available.
Reference Type
BACKGROUND
Guastella AJ, Mitchell PB, Mathews F. Oxytocin enhances the encoding of positive social memories in humans. Biol Psychiatry. 2008 Aug 1;64(3):256-8. doi: 10.1016/j.biopsych.2008.02.008. Epub 2008 Mar 17.
Reference Type
BACKGROUND
Bartz JA, Zaki J, Ochsner KN, Bolger N, Kolevzon A, Ludwig N, Lydon JE. Effects of oxytocin on recollections of maternal care and closeness. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21371-5. doi: 10.1073/pnas.1012669107. Epub 2010 Nov 29.
Reference Type
BACKGROUND
Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, Kolevzon A, Ochsner KN. Oxytocin selectively improves empathic accuracy. Psychol Sci. 2010 Oct;21(10):1426-8. doi: 10.1177/0956797610383439. Epub 2010 Sep 20. No abstract available.
Reference Type
BACKGROUND
Singer T, Snozzi R, Bird G, Petrovic P, Silani G, Heinrichs M, Dolan RJ. Effects of oxytocin and prosocial behavior on brain responses to direct and vicariously experienced pain. Emotion. 2008 Dec;8(6):781-91. doi: 10.1037/a0014195.
Reference Type
BACKGROUND
MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011 Sep;36(8):1114-26. doi: 10.1016/j.psyneuen.2011.02.015. Epub 2011 Mar 23.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GRANT11076934
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Intranasal Oxytocin on Emotion Regulation
NCT03055546
UNKNOWN
EARLY_PHASE1
The Effect of Oral Oxytocin and Atosiban on Social Attention
NCT07093060
RECRUITING
EARLY_PHASE1
Dose-dependent Effects of Oxytocin on the Amygdala and Reward System
NCT03846739
COMPLETED
PHASE1
The Influence of Oxytocin on Socio-communicative Sensitivity
NCT03096249
COMPLETED
PHASE1/PHASE2
Biological Basis of Individual Variation in Social Cooperation
NCT01566539
COMPLETED
NA
Neural Correlates of Empathogenic and Affiliative Actions of Oxytocin
NCT01701180
COMPLETED
EARLY_PHASE1
Oxytocin Administration and Emotion Recognition Abilities in Adults Reporting Adverse Childhood Experiences
NCT03335085
COMPLETED
NA
Oxytocin's Effect on Socioemotional Aging
NCT01823146
COMPLETED
NA
Oxytocin and the Processing of Social Stress-Associated Chemosignals
NCT03265899
COMPLETED
PHASE1
Neuropeptides and Social Behavior
NCT01680718
COMPLETED
EARLY_PHASE1
The Role of the Opioid System in Placebo Effects on Pain and Social Rejection
NCT04650841
NOT_YET_RECRUITING
EARLY_PHASE1
Effects of Oxytocin on Emotion Recognition and Response Inhibition
NCT02350946
UNKNOWN
PHASE2
Influence of Oxytocin on Resting State Neurophysiological Measures
NCT03255148
COMPLETED
PHASE1
The Effects of Intranasal and Oral Administration of Oxytocin on Responses to Emotional Scenes
NCT05532501
UNKNOWN
NA
Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making
NCT02526914
UNKNOWN
NA
Intranasal Oxytocin and Enhancement of Team Cohesion
NCT02302430
COMPLETED
PHASE1
Oxytocin and Social Behavior Over the Lifespan
NCT00914953
COMPLETED
EARLY_PHASE1
Oxytocin Buffers Stress Response in Individuals With Impaired Coping Abilities
NCT01065610
COMPLETED
NA
Temporal Dynamics and Pharmacokinetics of Intranasally Administered Oxytocin
NCT03011970
COMPLETED
PHASE1
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
NCT07140237
RECRUITING
EARLY_PHASE1
Effects of Intranasal Oxytocin and Vasopressin on Social Behavior
NCT01296269
UNKNOWN
NA
Oxytocin Effects on Self Versus Other Touch
NCT05899517
UNKNOWN
NA
Effects of Oxytocin on Reinforcement Learning
NCT03846271
UNKNOWN
NA
The Influence of Oxytocin on Automatic Imitation Behaviour in Healthy Adults
NCT01767025
COMPLETED
PHASE3
Oxytocin-augmented Cognitive-behavioral Group-based Short-term Intervention for Loneliness
NCT04137432
UNKNOWN
PHASE1